Apo-sucralfate
Apo-sucralfate Brand names, Apo-sucralfate Analogs
Apo-sucralfate Brand Names Mixture
- No information avaliable
Apo-sucralfate Chemical_Formula
C13H10N2O4
Apo-sucralfate RX_link
http://www.rxlist.com/cgi/generic2/thalidom.htm
Apo-sucralfate fda sheet
Apo-sucralfate msds (material safety sheet)
Apo-sucralfate Synthesis Reference
No information avaliable
Apo-sucralfate Molecular Weight
258.23 g/mol
Apo-sucralfate Melting Point
270 oC
Apo-sucralfate H2O Solubility
545 mg/L
Apo-sucralfate State
Solid
Apo-sucralfate LogP
-0.146
Apo-sucralfate Dosage Forms
Tablets for oral administration (50 mg); Capsules for oral administration (50 mg, 100 mg and 200 mg)
Apo-sucralfate Indication
For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Apo-sucralfate Pharmacology
Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans.
Apo-sucralfate Absorption
The absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen’s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract.
Apo-sucralfate side effects and Toxicity
The R-configuration and the S-configuration are more toxic individually than the racemic mixture. The LD50 could not be established in mice for racemic thalidomide, whereas LD50 values for the R and S configurations are reported to be 0.4 to 0.7 g/kg and 0.5 to 1.5 g/kg, respectively.
Apo-sucralfate Patient Information
Apo-sucralfate Organisms Affected
Humans and other mammals
